Iron Chelation and Multiple Sclerosis

Cites (227)

Items 201–228 of 228

1. The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice
   Vladislav Eybl, Dana Kotyzová, Metodı̀j Kolek, Jaroslav Koutensky, Peter Nielsen · 2002 · Toxicology Letters
2. Effect of deferoxamine on retinal lipid peroxidation in experimental uveitis.
   Guey‐Shuang Wu, Jonathan D. Walker, Narsing A. Rao · 1993 · PubMed
3. Iron accumulation in multiple sclerosis: an early pathogenic event
   Steven M. LeVine, Mehmet Bilgen, SHARON G. LYNCH · 2013 · Expert Review of Neurotherapeutics
4. Alternative treatment paradigm for thalassemia using iron chelators
   Natasha Szuber, Joan L. Buss, Shan Soe-Lin, Hady Felfly, Marie Trudel, Prem Ponka · 2008 · Experimental Hematology
5. Iron Status in Children With Recurrent Episodes of Tumefactive Cerebral Demyelination
   Ronald van Toorn, Johan F. Schoeman, Regan Solomons, Megan Rensburg, Susan J. van Rensburg · 2010 · Journal of Child Neurology
6. Preconditioning with cobalt chloride or desferrioxamine protects oligodendrocyte cell line (MO3.13) from tumor necrosis factor‐α‐mediated cell death
   Song‐Yi Yao, Mohammed Soutto, Subramaniam Sriram · 2008 · Journal of Neuroscience Research
7. Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis
   Antonia Ceccarelli, Maria Assunta Rocca, Elisabetta Perego, Lucia Moiola, Angelo Ghezzi, Vittorio Martinelli, Gıancarlo Comı, Massimo Filippi · 2011 · Multiple Sclerosis Journal
8. Induction of hypoxia inducible factor (HIF-1α) in rat kidneys by iron chelation with the hydroxypyridinone, CP94
   Jin Hyen Baek, Chad E.N. Reiter, Dominador J. Manalo, Paul W. Buehler, Robert C. Hider, Abdu I. Alayash · 2011 · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
9. Hypoxia inducible factor-1α mediates iron uptake which induces inflammatory response in amoeboid microglial cells in developing periventricular white matter through MAP kinase pathway
   Gurugirijha Rathnasamy, Eng‐Ang Ling, Charanjit Kaur · 2013 · Neuropharmacology
10. Inactivation of astrocytic glutamine synthetase by hydrogen peroxide requires iron
    Samantha P. Fernandes, Ralf Dringen, Alfons Lawen, Stephen R. Robinson · 2010 · Neuroscience Letters
11. Perihematomal glutamate level is associated with the blood–brain barrier disruption in a rabbit model of intracerebral hemorrhage
    Guofeng Wu, Shujie Sun, Fei Sheng, Likun Wang, Fan Wang · 2013 · SpringerPlus
12. Nitrative and oxidative modifications of enolase are associated with iron in iron-overload rats and in vitro
    Naihao Lu, Xueli Li, Jinyang Li, Wenjing Xu, Hailing Li, Zhonghong Gao · 2010 · JBIC Journal of Biological Inorganic Chemistry
13. Inhibition of allergic encephalomyelitis by the iron chelating agent desferrioxamine: differential effect depending on type of sensitizing encephalitogen
    David O. Willenborg, Narelle A. Bowern, Gytis Danta, Peter C. Doherty · 1988 · Journal of Neuroimmunology
14. Apoferritin Attenuates Experimental Allergic Encephalomyelitis in SJL Mice
    Steven M. LeVine, Smarajit Maiti, Mitchell R. Emerson, Tetyana V. Pedchenko · 2002 · Developmental Neuroscience
15. Comparison of Cytotoxic Aldehyde Generation in Beta-Thalassemia Patients Chelated with Deferoxamine or Deferiprone (L1) Versus NO Chelation
    Wally J. Bartfay, Denis C. Lehotay, Graham D. Sher, Emma Bartfay, Bev Tyler, Xiaoping Luo, Peter P. Liu · 1999 · Hematology
16. Glucosylated Deferiprone and Its Brain Uptake: Implications for Developing Glucosylated Hydroxypyridinone Analogues Intended to Cross the Blood−Brain Barrier
    Sourav Roy, Jane Elizabeth Preston, Robert C. Hider, Yong Ki Min · 2010 · Journal of Medicinal Chemistry
17. Update on a Patient with Superficial Siderosis on Deferiprone: Fig 1.
    Michael Levy, Rafael H. Llinas · 2012 · American Journal of Neuroradiology
18. Pathophysiology and Treatment of Neurodegeneration With Brain Iron Accumulation in the Pediatric Population
    Susanne A. Schneider, Giovanna Simonetta Zorzi, Nardo Nardocci · 2013 · Current Treatment Options in Neurology
19. Iron chelation therapy in the management of transfusion‐related cardiac iron overload
    Juliano Lara Fernandes · 2012 · Transfusion
20. Color atlas of multiple sclerosis and other myelin disorders
    Cedric S. Raine · 1989 · Journal of Neuroimmunology
21. Erratum
    1998 · NeuroImage
22. Conjugated Deferoxamine Reduces Blood-Brain Barrier Disruption in Experimental Optic Neuritis
    John R. Guy, Sue McGorray, Xioping Qi, Jeffrey R. Fitzsimmons, Anthony Mancuso, Narsing A. Rao · 2009 · Ophthalmic Research
23. Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing–remitting multiple sclerosis subjects
    Matthew E. Sweeney, Joyce G. Slusser, SHARON G. LYNCH, Stephen H. Benedict, Sharon L. Garcia, Laura Rues, Steven M. LeVine · 2011 · International Immunopharmacology
24. Iron chelation abrogates excessive formation of hydroxyl radicals and lipid peroxidation products in monocytes of patients with Eales' disease: Direct evidence using electron spin resonance spectroscopy
    Mohanraj Rajesh, Konerirajapuram Natarajan Sulochana, Sivaramakrishnan Ramakrishnan, Jyotirmay Biswas, P. T. Manoharan · 2004 · Current Eye Research
25. Teriflunomide for multiple sclerosis
    Dian He, Xu Zhu, Shuai Dong, Hong Zhang, Hongyu Zhou, Lu Wang, Shihong Zhang · 2012 · Cochrane Database of Systematic Reviews
26. Weiterer Beitrag zur Kenntnis der Hallervorden-Spatzschen Krankheit
    Ferenc Gallyas, St. K�rnyey · 1968 · European Archives of Psychiatry and Clinical Neuroscience
27. Differences in iron requirements by concanavalin A-treated and anti-CD3-treated murine splenic lymphocytes
    Solo R. Kuvibidila, Maria C. Velez, Lolie C. Yu, Raj Warrier, Bantval S. Baliga · 2002 · British Journal Of Nutrition
28. Clinical features of superficial siderosis
    Takemori Yamawaki · 2012 · Rinsho Shinkeigaku